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Highlights in this issue
The Journal on the rise
We have had very constructive editorial board meetings of HPB at our three regional meetings in the last few months and I 
thought that it would be helpful if I shared some of the outcomes from these with the broader HPB readership. We have been 
on a remarkable journey in the last few years as interest in journal content has risen as evidenced by an increasing readership, 
increased article downloads and an ascending impact factor.  We have endeavored to stimulate interest further through social me-
dia, virtual journal clubs, editorial highlights and editorial blogs. As is evident from this issue, HPB now attracts a broad variety of 
quality manuscripts that are both educational and add to the existing surgical evidence base. Last year, just over 450 manuscripts 
were submitted although it was only possible to accept 120 for publication in 2014. The higher rejection rate is inevitable as 
the competition for inclusion intensifi es.  Nonetheless, the Journal continues to be open to receipt of any quality paper and the 
editors would dispel the view held by some that certain areas of HPB practice might be off-limits for the Journal. The editorial 
team can only include subject matter based on  the content and quality of the submissions.  The turnaround time from receipt of 
a manuscript to a decision being made remains very short thanks to the tireless efforts of reviewers, the editorial board and my 
editorial colleagues. However, it is accepted that from time to time certain manuscripts may take longer to review and to process 
as we strive for quality and a consistent editorial style. AHPBA will move away from its mandatory manuscript submission policy 
in this coming year but we have been extremely fortunate in enjoying such strong support from the Americas during my time as 
Editor-in-Chief. We very much hope to hear of a further increase in impact factor in 2015 and expect that this will develop even 
greater interest in the Journal and add to the editorial workload.  We thank the readership for their support and would welcome 
any comments on how we might develop further HPB in the coming years.
James Garden
Inchinkoto induces liver antioxidant pathways but still to  demonstrate clinical ben-
eﬁ t in liver injury
There is considerable interest in fi nding a pharmacological means of inducing protective pathways in the liver. Key pathways that 
researchers have attempted to induce include the heat shock protein pathway, heme oxygenase-1 and other antioxidant pathways 
notably glutathione. A large number of drugs have been shown to have benefi t in preclinical and small animal studies but few 
translate to human trials. 
In this edition of HPB, Mizutani and colleagues from Nagoya, Japan, present a randomized controlled trial of Inchinkoto, a 
herbal medicine with potential hepatoprotective effects.  The same group has previously published evidence from preclinical 
studies in rats demonstrating a protective effect in animals undergoing major hepatectomy. There has also been interest in this 
compound which has been shown to reduce steatohepatitis in db/db mice fed a high fat diet.   
In the present study the authors administered inchinkoto for 7 days prior to major hepatectomy. No placebo was used because 
the drug has a very distinctive taste and so the study was also not blinded. The primary outcome measure of the study was post 
hepatectomy liver injury as measured by serum biochemistry. Although no clinical benefi t was seen in terms of reduced liver  injury 
or post hepatectomy liver failure scores it was evident from analysis of liver biopsies that the drug had a pharmacological action 
and induced antioxidant pathways in the liver as measured by the transcription factor Nrf-2 and the enzyme hemeoygenase-1. 
The authors are to be congratulated for performing this study and the failure to demonstrate clinical benefi t is probably more a 
refl ection of the multiple levels of protective pathways in the liver and general safety of surgery rather than a failing of the drug, fur-
thermore, the sample size is adequate to demonstrate pharmacological effi cacy but probably too small to rule out a clinical benefi t. 
Stephen J Wigmore
What is being done to prevent bile duct injury?
In this month’s issue of HPB, Stilling et al present a paper which is likely to become a seminal paper in the fi eld of bile duct injury 
(BDI). The paper analyses data from a national database that captured all bile duct injuries within Denmark and the subsequent 
management from 2005 to 2010. There are several unique factors with regard to this group of patients. Long term follow up is 
provided. In addition almost all patients were referred to fi ve dedicated HPB units for early primary repair, thus one could argue 
these patients were given the best chance of an optimal outcome.
The results make sober reading. The median age of the 139 patients who suffered a major bile duct injury was 46 years. Nine-
teen percent suffered concomitant vascular injury. Seventy-one percent had a Bismuth type 1 or 2 BDI. Median time to repair 
was 3 days and 83% were repaired within 2 weeks.
The initial median length of stay at the HPB centre was 11 days with an 11% reoperation rate. The 30 day intra-abdomi-
nal morbidity and mortality was 24% and 2% respectively. Long term (median follow up of those without problems was 114 
months) revealed a further 42% representing with a long term complication and 4% of patients died with complications from 
the BDI. Thirty percent of patients represented with biliary stricture requiring further intervention with almost all occurring 
within the fi rst two years. This is disappointing and it would be interesting to know the surgical detail of the reconstruction and, 
in particular, whether a left duct approach was the standard method of reconstruction for the hepaticojejunostomy. 
These results provide irrefutable evidence that BDI is a catastrophe for the patient. The profession needs to do everything it 
can to eliminate BDI. HPB surgeons need to take the lead to improve the standard of LC. Simply accepting that BDI’s are inevi-
table and are an acceptable risk of LC will do little to prevent another 139 patients in Denmark suffering the same fate in 5 years 
time. What does your institution have in place to help educate a surgeon that causes a BDI?
Saxon Connor
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